News archive
Showing 654 results
November 2017
-
Media Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
- Structural joint damage in psoriatic arthritis (PsA) patients taking Cosentyx® (secukinumab) was inhibited at 24 weeks versus placebo in all arms of the study(1)- PsA can lead to reduced mobility… -
Media Release
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
-
Media Release
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
- Primary results of pivotal Kymriah™ Phase II JULIET study in relapsed/refractory DLBCL- Post-hoc sub-analysis of crizanlizumab (SEG101, formerly SelG1) SUSTAIN trial evaluating time to first sickle… -
Media Release
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
October 2017
-
Media Release
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
- PARADIGMS data also show fingolimod-treated patients had significantly fewer new brain lesions vs. those on intramuscular interferon beta-1a injections(1)- Currently there are no disease-modifying… -
Media Release
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a
-
Media Release
Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
- "Hope" is inspired by the psoriasis community and Lauper's own experience living with the disease- Song and music video are available to stream at SEEMEtoknow.com- An estimated 7.5 million people… -
Media Release
Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
-
Media Release
Novartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
- Nearly 70% of patients maintained platelet counts of ≥30×10[9]/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding- More than one-third of patients permanently… -
Media Release
Novartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
September 2017
-
Media Release
Alcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaign
Consumer education campaign highlights the important role of vision in giving "everyday" athletes an invisible edge on and off the fieldNew survey uncovers that clear eyesight is more important than… -
Media Release
Alcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaign